$11.42
0[0.00%]
At close: May 7
$11.42
0[0.00%]
After Hours: 4:00PM EDT
Verastem
(NASDAQ:VSTM)Latest News for Verastem Stock (NASDAQ:VSTM)
Verastem Stock (NASDAQ: VSTM)
Categories: All
Tuesday, April 09, 2024
Tuesday, March 19, 2024
Friday, March 15, 2024
Thursday, March 14, 2024
Monday, March 11, 2024
Tuesday, March 05, 2024
- Verastem Oncology Secures FDA Orphan Drug Designation For Avutometinib Alone Or In Combination With Defactinib In Recurrent Low-Grade Serous Ovarian CancerBenzinga Newsdesk - Mar 5, 2024, 5:29PM
- Verastem Oncology Announces Preclinical Presentations For New Oral G12D Inhibitor And For Avutometinib And Defactinib Combination As A Backbone Of Therapy For RAS/MAPK Driven Cancers At AACR Annual Meeting 2024Benzinga Newsdesk - Mar 5, 2024, 4:37PM
Monday, February 12, 2024
Monday, January 29, 2024
Thursday, January 18, 2024
Tuesday, November 21, 2023
Wednesday, November 15, 2023
Wednesday, November 08, 2023
Friday, October 27, 2023
Thursday, October 26, 2023
Monday, October 16, 2023
Friday, September 29, 2023
Thursday, September 28, 2023
Wednesday, September 27, 2023
- Analyst Ratings for VerastemBenzinga Insights - Sep 27, 2023, 5:00PM
- Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023Benzinga Insights - Sep 27, 2023, 11:00AM
- B. Riley Securities Initiates Coverage On Verastem with Buy Rating, Announces Price Target of $21Benzinga Newsdesk - Sep 27, 2023, 5:08AM
Tuesday, August 29, 2023
Wednesday, August 09, 2023
Tuesday, August 08, 2023
Tuesday, July 11, 2023
- Truist Securities Maintains Buy Rating for Verastem: Here's What You Need To KnowBenzinga Insights - Jul 11, 2023, 1:00PM
- Truist Securities Maintains Buy on Verastem, Lowers Price Target to $39Benzinga Newsdesk - Jul 11, 2023, 8:11AM
- Verastem Oncology Announced That Dan Paterson, President & COO, Has Been Promoted To President & CCEO. Brian Stuglik Will Retire From The CEO Role And Remain A Board Member, Effective August 1Benzinga Newsdesk - Jul 11, 2023, 7:07AM
Thursday, July 06, 2023
Monday, July 03, 2023
Tuesday, June 27, 2023
Friday, June 23, 2023
Friday, June 16, 2023
- Why Clene Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving PremarketLisa Levin - Jun 16, 2023, 8:10AM
- Verastem Oncology shares are trading lower after the company priced its public offering of 7.2M shares at $9.75/share and pre funded warrants to purchase up to 1.5M shares at $9.749/warrant.Benzinga Newsdesk - Jun 16, 2023, 5:47AM
- Verastem Oncology Priced Its Underwritten Public Offering Of 7.18M Shares At $9.75/Share And Pre-funded Warrants To Purchase Up To 1.54M Shares At $9.749 Per Pre-funded Warrant, With Gross Proceeds Of Approximately $85MBenzinga Newsdesk - Jun 16, 2023, 5:44AM
Thursday, June 15, 2023
- Verastem Oncology Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants; No Terms DisclosedBenzinga Newsdesk - Jun 15, 2023, 4:00PM
- Crude Oil Rises Sharply; Jabil Posts Upbeat Q3 ResultsLisa Levin - Jun 15, 2023, 2:52PM
- Verastem's Ovarian Cancer Drug Showing Promise, Analyst Upgrades StockVandana Singh - Jun 15, 2023, 2:03PM
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Jun 15, 2023, 1:31PM
- Verastem shares are trading higher after Mizuho upgraded the stock to Buy from Neutral and raised the price target from $24 to $36Benzinga Newsdesk - Jun 15, 2023, 1:03PM
- Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023Benzinga Insights - Jun 15, 2023, 11:01AM
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Jun 15, 2023, 9:07AM
- Verastem To Rally Around 287%? Here Are 10 Other Analyst Forecasts For ThursdayLisa Levin - Jun 15, 2023, 8:10AM
- Mizuho Upgrades Verastem to Buy, Raises Price Target to $36Benzinga Newsdesk - Jun 15, 2023, 5:15AM